<DOC>
	<DOCNO>NCT01398592</DOCNO>
	<brief_summary>This study design assess potential difference Fasting Plasma Glucose ( FPG ) lower efficacy two DPP-4 inhibitor vildagliptin sitagliptin , two week treatment top metformin .</brief_summary>
	<brief_title>Vildagliptin Versus Sitagliptin - Differences Fasting Plasma Glucose Lowering Efficacy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Patients type 2 diabetes 18 85 year Metformin monotherapy &gt; 4 week HbA1c 6.5 9.5 % FPG &gt; 270 mg/dl Use antidiabetic drug metformin major cardiovascular event last 6 month ( MI , strokeâ€¦ )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Diabetes mellitus Type two</keyword>
	<keyword>T2DM</keyword>
	<keyword>vildagliptin</keyword>
	<keyword>sitagliptin</keyword>
	<keyword>FPG</keyword>
	<keyword>DPP-4</keyword>
</DOC>